Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDES-EXTRA
NCT04931667Phase 3Terminated
- Sponsor
- Biosplice Therapeutics
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lorecivivint in knee osteoarthritis (OA), sponsored by Biosplice Therapeutics. Primary endpoints: Change From Baseline in Pain Numeric Rating Scale Score for the Left Knee at 3 months and Change From Baseline in Pain Numeric Rating Scale Score for the Right Knee at 3 months. Started Jul 2021; status: terminated.
02
Drugs
lorecivivint
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04931667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931667.